Zymeworks to Acquire Theravance in Strategic Merger
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Zymeworks ( (ZYME) ) has issued an update.
On June 28, 2026, Zymeworks Inc. agreed to acquire Theravance Biopharma, Inc. through a merger in which Theravance will become a wholly owned subsidiary, with Theravance shareholders receiving $17 in cash per share plus a contingent value right tied to future monetization of ampreloxetine. The transaction adds the COPD drug YUPELRI, multiple royalty streams, a preclinical immunology and inflammation portfolio, and about $2.5 billion of Irish tax attributes, and is structured with a $350 million non-recourse note from OMERS Life Sciences and Theravance’s expected net cash, leaving Zymeworks to contribute $219 million at closing and positioning the deal to be earnings- and cash-flow-accretive while supporting Zymeworks’ capital-return and R&D investment strategy.
The merger remains subject to customary conditions, including antitrust clearance under the Hart-Scott-Rodino Act and approval by at least two-thirds of Theravance shareholders, with closing targeted for the second half of 2026 and reciprocal termination fees of about $32.5 million in certain scenarios. Zymeworks plans to complete Theravance’s restructuring to refocus on YUPELRI, retain and potentially externalize additional assets such as ampreloxetine via contingent value rights, and leverage steady YUPELRI profit-sharing and other royalties to fund its biotherapeutics pipeline, thereby broadening revenue diversification and potentially strengthening its standing among royalty-focused and specialty biotech peers.
The most recent analyst rating on (ZYME) stock is a Buy
with a $46.00 price target.
To see the full list of analyst forecasts on Zymeworks stock,
see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
The score is held back primarily by weak financial performance (persistent losses and significant cash burn, with revenue volatility) and bearish technical momentum. This is partially offset by a more constructive fundamental outlook from the latest earnings call and related corporate actions that improved liquidity and highlighted near-term regulatory catalysts and potential milestone upside.
To see Spark’s full report on ZYME stock,
click here.
More about Zymeworks
Zymeworks Inc. is a biotechnology company that manages a portfolio of licensed healthcare assets and develops a pipeline of novel, multifunctional biotherapeutics. The company focuses on combining partner-driven commercial cash flows with internal research and development to build a diversified, durable business and generate long-term value in areas such as chronic and serious diseases, including respiratory conditions like COPD.
Average Trading Volume: 659,050
Technical Sentiment Signal: Buy
Current Market Cap: $1.78B
See more insights into ZYME stock on TipRanks’ Stock Analysis page.
